EUVIMEDEUVIMED entdecken
Multizentrische Studie

Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma

Norikazu Tanabe, Issei Saeki, Kenji Yamaoka, Tomokazu Kawaoka, Tetsu Tomonari, Joji Tani, Takeshi Terashima, Yusuke Kawamura, Shiro Oka, Tetsuji Takayama, Hideki Kobara, Taro Yamashita und 3 weitere

Anticancer Research · 2025-03 · 45 (3) · 1117-1125

DOI: 10.21873/anticanres.17499 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Anticancer Research, online erschienen am 04.03.2025. Verfasst von Norikazu Tanabe und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan; norikazu@yamaguchi-u.ac.jp. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Bile Duct Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 10-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabBile Duct NeoplasmsCarcinoma, HepatocellularCholangiocarcinomaLiver NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedPhenylurea CompoundsProgression-Free SurvivalQuinolinesRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

Combined hepatocellular-cholangiocarcinomaatezolizumab plus bevacizumablenvatinib

Substanzen

Antibodies, Monoclonal, HumanizedatezolizumabBevacizumablenvatinibPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan; norikazu@yamaguchi-u.ac.jp.
  • Division of Laboratory, Yamaguchi University Hospital, Yamaguchi, Japan.
  • Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
  • Department of Gastroenterology, Hiroshima University Hospital, Hiroshima, Japan.
  • Department of Gastroenterology and Oncology, Institute of Biomedical Sciences, Tokushima University Graduate School of Medicine, Tokushima, Japan.
  • Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.

Zitieren

APA

Tanabe, N., Saeki, I., Yamaoka, K., Kawaoka, T., Tomonari, T., Tani, J., Terashima, T., Kawamura, Y., Oka, S., Takayama, T., Kobara, H., Yamashita, T., Akuta, N., Yamasaki, T., & Takami, T. (2025). Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma. Anticancer Research, 45(3), 1117-1125. https://doi.org/10.21873/anticanres.17499

Vancouver

Tanabe N, Saeki I, Yamaoka K, Kawaoka T, Tomonari T, Tani J, et al. Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma. Anticancer Research. 2025;45(3):1117-1125. doi:10.21873/anticanres.17499

BibTeX
@article{Tanabe2025,
  author = {Tanabe, Norikazu and Saeki, Issei and Yamaoka, Kenji and Kawaoka, Tomokazu and Tomonari, Tetsu and Tani, Joji and Terashima, Takeshi and Kawamura, Yusuke and Oka, Shiro and Takayama, Tetsuji and Kobara, Hideki and Yamashita, Taro and Akuta, Norio and Yamasaki, Takahiro and Takami, Taro},
  title = {Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma},
  journal = {Anticancer Research},
  year = {2025},
  volume = {45},
  number = {3},
  pages = {1117--1125},
  doi = {10.21873/anticanres.17499}
}
Kostenlos starten →